{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:33:31Z","timestamp":1789065211202,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jaclp.2020.12.013","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T18:38:39Z","timestamp":1610649519000},"page":"285-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report"],"prefix":"10.1016","volume":"62","author":[{"given":"Wilmarie Cidre","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2020.12.013_bib1","article-title":"Olanzapine - Compound Summary National Center for Biotechnology Information","year":"2020","journal-title":"National Library of Medicine"},{"key":"10.1016\/j.jaclp.2020.12.013_bib2","series-title":"FDA.gov website","article-title":"Zyprexa - Highlights of prescribing Information","year":"1997"},{"key":"10.1016\/j.jaclp.2020.12.013_bib3","series-title":"Life Threatening Psychopharmacological Emergencies: central anticholinergic syndrome (CAS); neuroleptic malignant syndrome (NMS) & serotonin toxicity syndrome (STS)","author":"Maldonado","year":"2019"},{"issue":"suppl 10","key":"10.1016\/j.jaclp.2020.12.013_bib4","first-page":"5","article-title":"Receptor pharmacology of neuroleptics: relation to clinical effects","volume":"60","author":"Richelson","year":"1999","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1139\/jpn.0332","article-title":"A\u00a0review of olanzapine-associated toxicity and fatality in overdose","volume":"28","author":"Chue","year":"2003","journal-title":"J\u00a0Psychiatry Neurosci"},{"key":"10.1016\/j.jaclp.2020.12.013_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0379-0738(97)00195-3","article-title":"Fatal overdose of olanzepine","volume":"91","author":"Elian","year":"1998","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.jaclp.2020.12.013_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15563650.2018.1485154","article-title":"Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center","volume":"57","author":"Boley","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaclp.2020.12.013_bib8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1176\/ajp.149.10.1393","article-title":"Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium","volume":"149","author":"Tune","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ccc.2008.06.004","article-title":"Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment","volume":"24","author":"Maldonado","year":"2008","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jaclp.2020.12.013_bib11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/gps.4823","article-title":"Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure","volume":"33","author":"Maldonado","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/geronj\/38.1.31","article-title":"The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations","volume":"38","author":"Blazer","year":"1983","journal-title":"J\u00a0Gerontol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/11631640-000000000-00000","article-title":"Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management","volume":"26","author":"Levine","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaclp.2020.12.013_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e32805aedf5","article-title":"Olanzapine overdose: a series of analytically confirmed cases","volume":"22","author":"Morgan","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.12839","article-title":"Pharmacological management of anticholinergic delirium - theory, evidence and practice","volume":"81","author":"Dawson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0196-0644(00)70057-6","article-title":"A\u00a0comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning","volume":"35","author":"Burns","year":"2000","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650.2017.1342828","article-title":"Safety and effectiveness of physostigmine: a 10-year retrospective review","volume":"56","author":"Arens","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaclp.2020.12.013_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.psym.2019.11.009","article-title":"A\u00a0study of the Psychometric Properties of the \"Stanford Proxy test for delirium\" (S-PTD): a New screening tool for the Detection of delirium","volume":"61","author":"Maldonado","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jaclp.2020.12.013_bib19","series-title":"Physostigmine for Anticholinergic Toxicity","first-page":"1","author":"Koy","year":"2003"},{"key":"10.1016\/j.jaclp.2020.12.013_bib21","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/15563650.2016.1245421","article-title":"2015 Annual report of the American association of poison control centers' National poison data system (NPDS): 33rd Annual report","volume":"54","author":"Mowry","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaclp.2020.12.013_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/0253-7176.207320","article-title":"Olanzapine-induced neuroleptic malignant syndrome","volume":"39","author":"Saha","year":"2017","journal-title":"Indian J Psychol Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF03160978","article-title":"Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine","volume":"5","author":"Morris","year":"2009","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0278-5846(02)00202-6","article-title":"Olanzapine-associated neuroleptic malignant syndrome","volume":"26","author":"Kontaxakis","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib26","first-page":"306","article-title":"Olanzapine-induced neuroleptic malignant syndrome","volume":"42","author":"Hosseini","year":"2017","journal-title":"Iran J Med Sci"},{"key":"10.1016\/j.jaclp.2020.12.013_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/ps.50.6.836a","article-title":"Olanzapine and NMS","volume":"50","author":"Hickey","year":"1999","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaclp.2020.12.013_bib28","first-page":"112","article-title":"Olanzapine as a cause of neuroleptic malignant syndrome, bibliographic review following a clinical case","volume":"46","author":"Garcia-Atienza","year":"2018","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.jaclp.2020.12.013_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1592\/phco.22.8.641.33211","article-title":"Atypical neuroleptic malignant syndrome associated with olanzapine","volume":"22","author":"Reeves","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaclp.2020.12.013_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0447.2005.00578.x","article-title":"Atypical neuroleptic malignant syndrome caused by olanzapine","volume":"112","author":"Nielsen","year":"2005","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaclp.2020.12.013_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-200302000-00016","article-title":"Olanzapine induced \"typical\" neuroleptic malignant syndrome","volume":"23","author":"Goveas","year":"2003","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib32","first-page":"123","article-title":"Reconsidering olanzapine as a possible Culprit for drug fever, defying \"Incomplete Neuromalignant syndrome","volume":"168","author":"Georges","year":"2016","journal-title":"J\u00a0La State Med Soc"},{"key":"10.1016\/j.jaclp.2020.12.013_bib33","doi-asserted-by":"crossref","DOI":"10.3371\/CSRP.WOWH.112316","article-title":"Cardiac arrest with clozapine and olanzapine: Revealing long QT syndrome","author":"Woloszyn","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.jaclp.2020.12.013_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/ncponc0718","article-title":"Lung carcinoma in African Americans","volume":"4","author":"Abidoye","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0269881108096901","article-title":"Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature","volume":"24","author":"Ahuja","year":"2010","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674370505000214","article-title":"Seizures, coma, and coagulopathy following olanzapine overdose","volume":"50","author":"Bhanji","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1345\/aph.10178","article-title":"Olanzapine-lnduced hyperglycemic nonketonic coma","volume":"35","author":"Roefaro","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaclp.2020.12.013_bib38","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4103\/jfmpc.jfmpc_405_16","article-title":"Seizure associated with olanzapine","volume":"7","author":"Uvais","year":"2018","journal-title":"J\u00a0Fam Med Prim Care"},{"key":"10.1016\/j.jaclp.2020.12.013_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1345\/aph.1C288","article-title":"Olanzapine-associated seizure","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaclp.2020.12.013_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1192\/bjp.178.1.85-a","article-title":"Lowered seizure threshold on olanzapine","volume":"178","author":"Woolley","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1520\/JFS15455J","article-title":"Fatality from olanzapine induced hyperglycemia","volume":"47","author":"Meatherall","year":"2002","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.jaclp.2020.12.013_bib42","doi-asserted-by":"crossref","first-page":"647476","DOI":"10.1155\/2013\/647476","article-title":"Risk of Mortality (including Sudden cardiac death) and Major cardiovascular events in Users of olanzapine and other antipsychotics: a study with the general practice research Database","volume":"2013","author":"Jones","year":"2013","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1520\/JFS14697J","article-title":"Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic?","volume":"45","author":"Robertson","year":"2000","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.jaclp.2020.12.013_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00000433-200009000-00013","article-title":"Overdose and death with olanzapine: two case reports","volume":"21","author":"Gerber","year":"2000","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.24869\/psyd.2017.90","article-title":"Postinjection delirium\/sedation syndrome (PDSS) following olanzapine long-acting injection: a case report","volume":"29","author":"Uglesic","year":"2017","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.jaclp.2020.12.013_bib46","first-page":"433","article-title":"Olanzapine and delirium: lesson from clinical practice","volume":"42","author":"Singh","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13651500410005568","article-title":"Occurrence of delirium after a short-term intake of olanzapine","volume":"8","author":"Simhandl","year":"2004","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3","key":"10.1016\/j.jaclp.2020.12.013_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0885-3924(98)00128-6","article-title":"Complicated delirium in a cancer patient successfully treated with olanzapine","volume":"17","author":"Passik","year":"1999","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jaclp.2020.12.013_bib49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/psyg.12195","article-title":"Delirium associated with olanzapine use in the elderly","volume":"17","author":"Park","year":"2017","journal-title":"Psychogeriatrics"},{"issue":"2","key":"10.1016\/j.jaclp.2020.12.013_bib50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpainsymman.2004.04.008","article-title":"Olanzapine-induced delirium in a terminally ill cancer patient","volume":"28","author":"Morita","year":"2004","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"suppl 2","key":"10.1016\/j.jaclp.2020.12.013_bib51","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.21037\/apm.2017.06.04","article-title":"Olanzapine induced delirium-a \"probable\" adverse drug reaction","volume":"6","author":"MacKintosh","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib52","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1176\/jnp.23.2.jnpe54","article-title":"Delirium associated with olanzapine therapy in an elderly man with bipolar affective disorder","volume":"23","author":"Aggarwal","year":"2011","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.jaclp.2020.12.013_bib53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0004867420927465","article-title":"Monitoring for post-injection delirium\/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic","volume":"54","author":"Siskind","year":"2020","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib54","first-page":"1","article-title":"A\u00a0randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome","author":"Wang","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaclp.2020.12.013_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00000542-200601000-00005","article-title":"Lorazepam is an independent risk factor for transitioning to delirium in\u00a0intensive care unit patients","volume":"104","author":"Pandharipande","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jaclp.2020.12.013_bib56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ccc.2017.03.013","article-title":"Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium","volume":"33","author":"Maldonado","year":"2017","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jaclp.2020.12.013_bib57","article-title":"Physostigmine National Center for Biotechnology Information","author":"Andrade","year":"2020"},{"key":"10.1016\/j.jaclp.2020.12.013_bib58","series-title":"Physostigmine","author":"Andrade","year":"2020"},{"key":"10.1016\/j.jaclp.2020.12.013_bib59","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0021-9258(18)33170-3","article-title":"Acetylcholine and oxidative metabolism in septum and hippocampus in\u00a0vitro","volume":"258","author":"Gibson","year":"1983","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaclp.2020.12.013_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0922-4106(95)00080-1","article-title":"Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells","volume":"290","author":"Storch","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/10799899509045225","article-title":"Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction","volume":"15","author":"Maelicke","year":"1995","journal-title":"J\u00a0Recept Signal Transduct Res"},{"key":"10.1016\/j.jaclp.2020.12.013_bib62","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1016\/S0021-9258(17)34075-9","article-title":"Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide","volume":"269","author":"Schroder","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaclp.2020.12.013_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/15563657709046281","article-title":"Reversal by physostigmine of clozapine-induced delirium","volume":"10","author":"Schuster","year":"1977","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.1975.01760210109008","article-title":"Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs","volume":"32","author":"Granacher","year":"1975","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib65","first-page":"433","article-title":"[On the mechanism of action of the lipolytic effect of physostigmine]","volume":"252","author":"Stock","year":"1966","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib66","first-page":"235","article-title":"[Physostigmine--recent pharmacologic data and their significance for practical use]","volume":"14","author":"Rupreht","year":"1989","journal-title":"Anaesthesiol Reanim"},{"key":"10.1016\/j.jaclp.2020.12.013_bib67","author":"Andrade"},{"key":"10.1016\/j.jaclp.2020.12.013_bib68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.annemergmed.2009.01.023","article-title":"Expert consensus\u00a0guidelines for stocking of antidotes in hospitals that provide emergency care","volume":"54","author":"Dart","year":"2009","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib69","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0196-0644(80)80232-0","article-title":"Asystole complicating physostigmine treatment of tricyclic antidepressant overdose","volume":"9","author":"Pentel","year":"1980","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40263-014-0216-9","article-title":"Post-injection delirium\/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management","volume":"29","author":"Luedecke","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaclp.2020.12.013_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/24734306.2018.1535538","article-title":"Revival of an antidote: bedside experience with physostigmine","volume":"2","author":"Rasimas","year":"2018","journal-title":"Toxicol Commun"},{"key":"10.1016\/j.jaclp.2020.12.013_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1067\/mem.2003.232","article-title":"Complications of diagnostic physostigmine administration to emergency department patients","volume":"42","author":"Schneir","year":"2003","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0735-6757(98)90003-1","article-title":"Treatment of acute anticholinergic poisoning with physostigmine","volume":"16","author":"Beaver","year":"1998","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jaclp.2020.12.013_bib74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13181-014-0452-x","article-title":"Toxicology Investigators Consortium i. The Use of physostigmine by Toxicologists in anticholinergic toxicity","volume":"11","author":"Watkins","year":"2015","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.jaclp.2020.12.013_bib75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/appi.ajp.157.2.304-a","article-title":"Intoxication with olanzapine","volume":"157","author":"Bosch","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib76","first-page":"463","article-title":"Continuous infusion of physostigmine in anticholinergic delirium: case report","volume":"44","author":"Stern","year":"1983","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.013_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/15563650600584535","article-title":"Altered mental status from olanzapine overdose treated with physostigmine","volume":"44","author":"Weizberg","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaclp.2020.12.013_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/15563650.2013.773006","article-title":"Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient","volume":"51","author":"Hail","year":"2013","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266729602100001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266729602100001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:09:26Z","timestamp":1762643366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266729602100001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S266729602100001X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.013","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}